Home MNC China Lens

MNC CHINA LENS

October 23, 2025

Partners, not sellers: how Innovent's Co-Co deal is reshaping China's role in global pharma

The recent landmark deal provides a tangible blueprint for the next phase of China's innovative drugs going global.

October 22, 2025

Innovent inks $11.4 Billion cancer drug deal with Takeda, sets new China biotech benchmark

October 17, 2025

Up to $1.53B: Hansoh grants Roche an exclusive license to novel CDH17-targeting ADC HS-20110

October 16, 2025

Pregene, Kite partner on next-gen therapies in potential $1.64B deal

October 14, 2025

Boehringer Ingelheim’s "China Key" strategy advances with launch of local Trajenta® production

October 14, 2025

AbbVie's TrenibotE files for market approval in China

October 13, 2025

Merck's Erbitux® (cetuximab) gains new indication for colorectal cancer in China

October 12, 2025

Milestone achievement in BMS collaboration: Biokin Pharmaceutical to receive $250 million payment

October 11, 2025

UCB’s zilucoplan, world’s first subcutaneous C5 inhibitor for gMG, approved in China

September 30, 2025

RemeGen and Santen announce NDA acceptance in China for RC28-E in diabetic macular edema

September 29, 2025

Eisai and Biogen's LEQEMBI® (lecanemab) IV maintenance dosing for early Alzheimer’s disease approved in China

September 27, 2025

Daiichi Sankyo initiates phase III trial of ifinatamab deruxtecan (I-DXd) in China for advanced esophageal cancer

September 26, 2025

Otsuka Pharmaceutical’s PDE4 inhibitor Difamilast files for approval in China

September 26, 2025

China as the "accelerator" for rare disease drug development: insights from Dr. Gianluca Pirozzi & AstraZeneca’s rare disease strategy

September 25, 2025

Why Eisai’s DAYVIGO and Simcere’s QUVIVIQ are the hottest new insomnia drugs on China’s e-commerce platforms

September 23, 2025

AbbVie submits new indication application for epcoritamab in China

September 22, 2025

AstraZeneca initiates Phase III clinical trial in China for its oral small-molecule PCSK9 inhibitor AZD0780

September 20, 2025

EC approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively

September 20, 2025

Chinese CGM enterprises and Abbott engaged in a protracted patent battle

September 19, 2025

GE Healthcare said to explore stake sale in China unit

September 17, 2025

AstraZeneca's Breztri submitted for marketing approval in China